Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [electronic resource]
Producer: 20080306Description: 827-34 p. digitalISSN:- 0835-7900
- Administration, Oral
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal -- administration & dosage
- Colitis, Ulcerative -- diagnosis
- Delayed-Action Preparations
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Male
- Mesalamine -- administration & dosage
- Middle Aged
- Retrospective Studies
- Severity of Illness Index
- Sigmoidoscopy
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.